Healthcare
Immuneering Corporation(IMRX)
Live Price
Offline$4.41
+0.00% today
Window Change
-23.05%
Window
May 29, 2026 โ Jun 22, 2026
- Market Cap
- $190.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +37.7%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars ยท May 29, 2026 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immuneering Corporation (IMRX) is a Healthcare stock with a market cap of $190.00M and listed on NASDAQ. The stock last traded around $4.41 and down 23.1% across the available one-year price window (May 29, 2026 โ Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +37.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +37.7%, free cash flow +17.4% with operating margin 0.0% and ROIC -26.7%. Stock Foundry combines IMRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +37.7%, while operating margin sits near 0.0%.
Benchmark Edge
IMRX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IMRX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IMRX Max Drawdown
-32.06%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IMRX and SPY.
Company Overview
Immuneering Corporation
NASDAQ Global Market
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
- Leadership
- Benjamin J. Zeskind
- IPO Date
- Jul 30, 2021
- Employees
- 54
- Street Address
- 245 Main Street
- Mailing
- Cambridge, MA, 02142
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 500 8080
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.1
Growth
- Revenue
- 0.0%
- EPS
- +37.7%
- Free Cash Flow
- +17.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -43.3%
- ROIC
- -26.7%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 17.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.